Table 1.
Gene | Gene Function | Domains/Motifs | Disease | Distance ofFurthest Breakpointa(kb) | 3′ or 5′ Side | Reference |
PAX6 | TF | Paired box and homeodomain | Aniridia | 125 | 3′ | Kleinjan et al. 2001 |
TWIST | TF | … | Saethre-Chotzen syndrome | 260 | 3′ | Cai et al. 2003 |
POU3F4 | TF | POU homeodomain | X-linked deafness | 900 | 5′ | de Kok et al. 1996 |
PITX2 | TF | Homeodomain | Rieger syndrome | 90 | 5′ | Trembath et al. 2004 |
GLI3 | TF | Zinc finger | Greig cephalopolysyndactyly syndrome | 10 | 3′ | Wild et al. 1997 |
MAF | TF | bZIP | Cataract, ocular anterior segment dysgenesis, and coloboma | 1,000 | 5′ | Jamieson et al. 2002 |
FOXC1 | TF | Forkhead | Glaucoma/autosomal dominant iridogoniodysgenesis | 25/1,200 | 5′ | Davies et al. 1999 |
FOXC2 | TF | Forkhead | Lymphedema distichiasis | 120 | 3′ | Fang et al. 2000 |
FOXL2 | TF | Forkhead | Blepharophimosis-ptosis-epicanthus inversus syndrome | 170 | 5′ | Crisponi et al. 2004 |
SOX9 | TF | HMG box | Campomelic dysplasia | 850 | 5′ | Bagheri-Fam et al. 2001; Pop et al. 2004 |
SRY | TF | HMG box | Sex reversal | 3 | 5′/3′ | McElreavy et al. 1992 |
SIX3 | TF | Homeodomain | Holoprosencephaly (HPE2) | <200 | 5′ | Wallis et al. 1999 |
SHH | Signaling | … | Holoprosencephaly (HPE3) | 265 | 5′ | Roessler et al. 1997 |
SHH | Signaling | … | Preaxial polydactyly | 1,000 | 5′ | Lettice et al. 2003 |
SHFM1 | TF | DLX5/DLX6? | Split-hand/split-foot malformation | ∼450 | 5′/3′ | Crackower et al. 1996 |
FSHD | ?? | … | Facioscapulohumeral dystrophy | 100 | 3′ | Gabellini et al. 2002; Jiang et al. 2003; Masny et al. 2004 |
HBB | Oxygen carrier | Globin | γβ-Thalassemia | 50 | 5′ | Kioussis et al. 1983 |
HBA | Oxygen carrier | Globin | α-Thalassemia | 18 | 3′ | Tufarelli et al. 2003 |
Hoxd complex | TF | Homeodomain | Mesomelic dysplasia and vertebral defects | 60 | 3′ | Spitz et al. 2002 |
LCT | Enzyme | Lactase | Lactase persistence | 15/20 | 5′ | Enattah et al. 2002 |
Note.— TF = transcription factor.
In the case of 3′ breakpoints, the distance refers to the distance from the breakpoint to the 3′ end of the gene or complex.